ASCO 2022

Breast Cancer

Sacituzumab govitecan meets primary endpoint 

Presented By

Prof. Hope Rugo, University of California San Francisco, CA, USA

Trial

Phase 3, TROPiCS-02

Conference

ASCO 2022

5 August, 2022 12:11

Shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer 

Presented By

Prof. Richard Finn, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, PALOMA-2

Conference

ASCO 2022

5 August, 2022 12:09

Practice-changing results of T-DXd in HER2-low breast cancer 

Presented By

Prof. Shanu Modi, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DESTINY-Breast04

Conference

ASCO 2022

5 August, 2022 12:04

SET2,3 to inform on chemotherapy decisions in ER-positive breast cancer

Presented By

Dr Otto Metzger, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, CALGB9741

Conference

ASCO 2022

5 August, 2022 11:59

Metastasis-directed therapy fails in oligometastatic breast cancer

Presented By

Dr Steven Chmura, University of Chicago, IL, USA

Trial

Phase 2, NRG-BR002

Conference

ASCO 2022

5 August, 2022 11:34

Analysis by residual cancer burden further clarifies effect of pembrolizumab

Presented By

Prof. Lajos Pusztai, Yale School of Medicine, CT, USA

Trial

Phase 3, KEYNOTE-522

Conference

ASCO 2022

5 August, 2022 11:26

Contribution of metastatic therapies on mortality reduction in breast cancer

Presented By

Prof. Jennifer Caswell-Jin, Stanford University, CA, USA

Conference

ASCO 2022

5 August, 2022 11:19

Radiotherapy may be omitted in breast cancer patients 

Presented By

Prof. Timothy Whelan, McMaster University, Canada

Trial

LUMINA

Conference

ASCO 2022

5 August, 2022 10:59

Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer

Presented By

Prof. Kevin Kalinsky, Winship Cancer Institute of Emory University, GA, USA

Trial

Phase 2, MAINTAIN

Conference

ASCO 2022

5 August, 2022 10:53

7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups

Presented By

Dr Pat Whitworth, Nashville Breast Cancer Center, TN, USA

Conference

ASCO 2022

5 August, 2022 10:44

Lung Cancer

Additional tiragolumab does not help patients with untreated small cell lung cancer 

Presented By

Dr Charles Rudin, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, SKYSCRAPER-02

Conference

ASCO 2022

5 August, 2022 12:42

Success for serplulimab plus chemotherapy in small cell lung cancer

Presented By

Prof. Ying Cheng, Jilin Cancer Hospital, China

Trial

Phase 3, ASTRUM-005

Conference

ASCO 2022

5 August, 2022 12:38

Adagrasib safe and clinically active in non-small cell lung cancer

Presented By

Dr Alexander Spira, Virginia Cancer Specialists Research Institute, VA, USA

Trial

Phase 2, KRYSTAL-1

Conference

ASCO 2022

5 August, 2022 12:33

Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer

Presented By

Prof. Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center, Australia

Trial

Phase 3, CheckMate 227

Conference

ASCO 2022

5 August, 2022 12:29

Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer

Presented By

Dr Oladimeji Akinboro, US Food and Drug Administration, MD, USA

Conference

ASCO 2022

5 August, 2022 12:26

Melanoma

First results on distant metastasis-free survival in stage II melanoma 

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 3, KEYNOTE-716

Conference

ASCO 2022

5 August, 2022 13:54

Higher response rates for concurrent triple therapy versus sequential therapy in melanoma

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 2, NeoTrio

Conference

ASCO 2022

5 August, 2022 13:50

Genitourinary Cancers

Exploratory treatment options fail in ccRCC 

Presented By

Prof. Thomas Powles, University of London, UK

Trial

Phase 2, CALYPSO

Conference

ASCO 2022

5 August, 2022 14:18

Adjuvant everolimus did not benefit high-risk renal cell carcinoma 

Presented By

Dr Christopher W. Ryan, Oregon Health & Science University, OR, USA

Trial

Phase 3, EVEREST

Conference

ASCO 2022

5 August, 2022 14:14

Cabozantinib fails as first-line maintenance therapy in urothelial cancer

Presented By

Prof. Robert Jones, University of Glasgow, UK

Trial

Phase 2, ATLANTIS

Conference

ASCO 2022

5 August, 2022 14:11

177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC

Presented By

Prof. Michael Hofman, Peter McCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO 2022

5 August, 2022 14:08

Enzalutamide performs well in metastatic hormone-sensitive prostate cancer

Presented By

Prof. Ian Davis, Monash University, Australia

Trial

Phase 3, ENZAMET

Conference

ASCO 2022

5 August, 2022 14:04

Haematologic Malignancies

Autologous stem cell transplantation plus RVd improves PFS in multiple myeloma  

Presented By

Prof. Paul Richardson, Harvard Medical School, MA, USA

Trial

Phase 3, DETERMINATION

Conference

ASCO 2022

5 August, 2022 14:33

Novel first-line treatment option for mantle cell lymphoma 

Presented By

Prof. Michael Wang, Anderson Cancer Center, TX, USA

Trial

Phase 3, SHINE

Conference

ASCO 2022

5 August, 2022 14:30

Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma

Presented By

Prof. Juan Du, Shanghai Chang Zheng Hospital, China

Conference

ASCO 2022

5 August, 2022 14:24

Gastrointestinal Cancers

Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer  

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO 2022

5 August, 2022 15:19

Spectacular results for dostarlimab in mismatch repair deficient rectal cancer 

Presented By

Dr Andrea Cercek, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO 2022

5 August, 2022 15:14

Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases

Presented By

Prof. Cornelis Punt, University Medical Center Utrecht, the Netherlands

Trial

Phase 3, CAIRO5

Conference

ASCO 2022

5 August, 2022 15:11

To resect or not to resect primary tumours in stage IV colon cancer?

Presented By

Prof. Jürgen Weitz, Technische Universität Dresden, Germany

Trial

SYNCHRONOUS

Conference

ASCO 2022

5 August, 2022 15:08

Novel treatment option for KRAS wildtype pancreatic cancer 

Presented By

Prof. Shukui Qin, Cancer Center of Jinling Hospital, China

Trial

Phase 3, NOTABLE

Conference

ASCO 2022

5 August, 2022 15:03

Gynaecological Cancers

Primary results of rucaparib in ovarian cancer 

Presented By

Prof. Bradley Monk, University of Arizona, AZ, USA

Trial

Phase 3, ATHENA-MONO

Conference

ASCO 2022

5 August, 2022 15:28

Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer 

Presented By

Dr Domenica Lorusso, San Raffaele Scientific Institute, Italy

Trial

Phase 3, MIT023

Conference

ASCO 2022

5 August, 2022 15:25

Encouraging results of relacorilant in ovarian cancer

Presented By

Prof. Nicoletta Colombo, University of Milan, Italy

Conference

ASCO 2022

5 August, 2022 15:23

Miscellaneous Topics

Bacterial decolonisation effective against radiation dermatitis

Presented By

Ms Yana Kost, Albert Einstein College of Medicine, NY, USA

Conference

ASCO 2022

5 August, 2022 15:38

New standard-of-care for cisplatin-ineligible locally advanced head and neck squamous cell carcinoma

Presented By

Prof. Vanita Noronha, Tata Memorial Hospital, India

Conference

ASCO 2022

5 August, 2022 15:35

Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma 

Presented By

Dr Martin McCabe, University of Manchester, UK

Trial

Phase 3, rEECur

Conference

ASCO 2022

5 August, 2022 15:32

Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma 

Presented By

Prof. Eric Bouffet, University of Toronto, Canada

Conference

ASCO 2022

5 August, 2022 15:30